Jornal de pesquisa e terapia com células-tronco

Abstrato

Metadichol^® and CD34 Expression in Umbilical Cord Cells

Raghavan PR

Umbilical cord blood has found use in the clinic for more than 40 years in hematopoietic stem cell transplantation therapies to treat patients with bone marrow diseases or to reconstitute the bone of those cancer patients who had to have theirs wiped out to cure their leukemia or lymphoma. A feature is the presence of CD34 antigen in of hematopoietic stem and progenitor cells. These cells can differentiate and are self-renewing, multipotent stem cells that give rise to all blood cells of the immune system and erythrocytes), and lymphoid (T cells, B cells, and NK cells) lineages. This study describes increased CD34 gene expression in Umbilical Cord (UC) cells upon treatment with Metadichol which is an inverse agonist of AHR (Aryl Hydrocarbon Receptor). UC cells were subjected to treatment at one picogram, 100 picograms, 1 nanogram, 100 nanograms and 1 microgram per ml of Metadichol for 72 hrs. Cells treated at 1ng have shown the highest increase in expression of CD34 compared to untreated Control. The cells treated with 1 pg, 100 picogram/ml demonstrated the multiplicity of CD34 expression as indicated by peak shift compared to treatment with 1ng, 100 ng, and 1 μg